ArticleFrontiers in molecular biosciences2025
Bromo- and chloro-substituted flavones induce apoptosis and modulate cell death pathways in canine lymphoma and leukemia cells - a comparative
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure-Activity Relationships of Hemocompatible Cationic 6-Azaindole Pyridinium Salts: Antimicrobial and Anticancer Activity.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although flavonoids are natural compounds with anti-cancer potential, their clinical application is limited due to the low bioavailability. Structural modification, such as halogenation, has been identified as a strategy to enhance drug-like properties. The rationale behind this is that halogen substituents can increase lipophilicity, alter electronic distribution, and improve interactions with cellular targets. Here, we investigated the cytotoxic mechanisms of three halogenated flavones - 4'-chloroflavone (Cl-F), 6,8-dichloroflavone (DiCl-F), and 8-bromo-6-chloroflavone (BrCl-F) - in two canine B-cell models, CLB70 (leukemia) and CLBL-1 (lymphoma), chosen for their translational relevance to human hematological cancers. Methods: Cytotoxicity was assessed by MTT assay, apoptosis by annexin V/PI staining, Bcl-2 and Bcl-XL expression by Western blotting, cell cycle distribution by flow cytometry, and DNA damage by changes in H2AX phosphorylation. Results: BrCl-F demonstrated the strongest cytotoxic activity, significantly reducing metabolic activity and increasing the proportion of apoptotic cells in both cell lines. In CLB70 cells, BrCl-F treatment was accompanied by decreased expression of Bcl-2 and Bcl-XL. DiCl-F showed moderate cytotoxicity but induced a marked increase in γH2AX levels and accumulation of cells in the G2/M phase. Cl-F exhibited weaker effects and reduced cell viability primarily at higher concentrations. Conclusion: Halogenated flavones display distinct cytotoxic profiles in canine B-cell leukemia and lymphoma models, with BrCl-F showing the highest anticancer activity. These findings support further investigation of halogenated flavones as potential anticancer agents in comparative oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.